Moderna CEO Stephane Bancel Bought $5 Million in MRNA Stock at $31 — His First Open-Market Purchase
After selling $1.19 billion in Moderna shares since 2008, CEO Stephane Bancel reversed course and bought 160,000 shares at ~$31 in March 2025 — a rare bullish signal at multi-year lows.
Stephane Bancel, CEO of Moderna (MRNA), bought $5.2 million worth of company stock in March 2025 — his first open-market purchase on record. The buy came at a price of roughly $31 per share, near the stock's multi-year low and a 93% decline from its 2021 pandemic highs above $450. After years of systematic selling totaling $1.19 billion, the reversal is a striking signal from an insider who knows the company's pipeline better than anyone.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $1.19 billion |
| Career Buy Value | $5.2 million |
| Total Transactions | 1,701 |
| First Transaction | Aug 25, 2008 |
| Last Transaction | Dec 11, 2025 |
| Shares Remaining | 6,181,970 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| Dec 11, 2025 | Exercise | 688,073 | $10.90 | $7.5M (options) |
| Mar 3, 2025 | Buy | 57,493 | $31.53 | $1.81M |
| Mar 3, 2025 | Buy | 102,821 | $31.04 | $3.19M |
| Mar 1, 2025 | Award | 357,065 | $30.96 | — |
| Feb 12, 2025 | Tax | 6,400 | $30.93 | $198K (tax) |
| Feb 16, 2024 | Sell | 26,351 | $88.88 | $2.34M |
The headline event is Bancel's March 3, 2025 open-market purchases: 160,314 shares bought across two transactions at $31.04–$31.53, totaling $5 million in new investment. This came just days after receiving a 357,000-share stock award, suggesting conviction beyond standard compensation. In December 2025, he exercised 688,073 options at $10.90, converting vested derivatives into common stock — a routine execution, but one that brings his total holding to 6.18 million shares.
What It Means
CEO open-market buys are among the strongest insider signals tracked by professional investors, and for good reason: executives use their own money to buy shares they could acquire for free through options. Bancel's $5 million purchase is especially notable given his history. He had sold $1.19 billion in MRNA stock over 17 years — much of it during the pandemic windfall when the stock traded above $400. To then deploy $5 million of personal capital at $31, near an all-time trough, implies a CEO who believes the market is dramatically undervaluing the company's non-COVID pipeline, which includes cancer vaccines and respiratory combination shots in late-stage trials.
What to Watch
- Whether Bancel adds to his position if MRNA continues to trade below $40 — repeat insider buys at depressed levels are the highest-conviction signal in the playbook
- Pipeline catalysts in 2025–2026: flu/COVID combo vaccine data, cancer vaccine (mRNA-4157) trial results, and RSV program updates
- Whether other Moderna insiders follow the CEO's lead with their own open-market purchases
Breaking News Editor at 13F Insight. First to report on major SEC filings, institutional moves, and regulatory developments.
More from Alex →Add the funds and stocks mentioned here to a free watchlist, or get an email the next time they file — no card required.